Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 7/20 | 0.34 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | CTSB | P07858 | 4/20 | 0.33 |
| ▸ | CTSH | P09668 | 3/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11606375 | 0.87 | — | — | |
| SCHEMBL3155857 | 0.85 | CYP1A2 (0.40) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL1899034 | 0.82 | CTSK (0.33) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL7087843 | 0.80 | CYP1A2 (0.37) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL2422889 | 0.78 | SHBG (0.42) | CYP1A2CTSKCTSLCTSB | |
| SCHEMBL14261875 | 0.76 | CTSK (0.39) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL12631778 | 0.76 | CTSK (0.39) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL19003120 | 0.76 | CYP1A2 (0.34) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL11746493 | 0.76 | CYP1A2 (0.34) | CYP1A2CTSKCTSLCTSBCTSH | |
| SCHEMBL12632301 | 0.76 | EPHX1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019002788-A1 | UREAS FOR SEPARATING URANIUM(VI) AND PLUTONIUM(IV) WITHOUT REDUCING THE PLUTONIUM(IV) | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-01-03 | — | — | WO | disclosed |
| WO-2014128206-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128213-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1603553-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | disclosed |
| EP-0555331-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS. | SEARLE & CO (US) | 1993-08-18 | — | — | EP | disclosed |